LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Bank of America Corp DE

Bank of America Corp DE lifted its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 32.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,752 shares of the medical instruments supplier's stock after buying an additional 15,250 shares during the period. Bank of America Corp DE owned approximately 0.27% of LeMaitre Vascular worth $5,690,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of LMAT. Allspring Global Investments Holdings LLC grew its position in LeMaitre Vascular by 48.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after purchasing an additional 4,330 shares during the last quarter. Invesco Ltd. grew its position in LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares during the last quarter. Compass Planning Associates Inc purchased a new position in LeMaitre Vascular during the 4th quarter worth $567,000. Barclays PLC grew its position in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after purchasing an additional 29,180 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in LeMaitre Vascular by 31.8% during the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock worth $9,385,000 after purchasing an additional 24,586 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Performance

LMAT stock traded up $1.10 during trading on Friday, reaching $82.17. 166,962 shares of the company were exchanged, compared to its average volume of 168,628. The company has a market cap of $1.86 billion, a P/E ratio of 44.90, a PEG ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The stock's 50 day moving average price is $83.86 and its 200 day moving average price is $91.65.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.44 EPS. As a group, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's payout ratio is currently 40.40%.

Analysts Set New Price Targets

Several research analysts have issued reports on LMAT shares. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price on the stock. Lake Street Capital lifted their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $97.83.

Insiders Place Their Bets

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the transaction, the insider now owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO George W. Lemaitre sold 4,399 shares of LeMaitre Vascular stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total transaction of $374,354.90. Following the transaction, the chief executive officer now owns 1,827,003 shares of the company's stock, valued at approximately $155,477,955.30. The trade was a 0.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 102,009 shares of company stock worth $8,721,836. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.